Laser therapy for nerve damage from anti-MAG antibodies
Part of Blood & lymphatic, Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether a specific type of light therapy (photobiomodulation) can improve symptoms of nerve damage (peripheral neuropathy) caused by anti-MAG antibodies. If you have this condition, this trial might offer a new way to manage your symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood protein called IgM gammopathy with anti-MAG antibodies
- You have symptoms of nerve damage (like numbness, tingling, or weakness) in your arms or legs
- You agree to take part in the study
- You do not have a solid tumor in areas that would be exposed to the laser
- You are not under legal guardianship or conservatorship
- Your nerve damage is not caused by another condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests rituximab, an antibody medicine, for people with a particular type of nerve damage called anti-MAG–related demyelinating polyneuropathy. It aims to see if rituximab improves symptoms or function in patients who are considered “good responders.”
This study looks at how nerves work and their structure in people with Charcot-Marie-Tooth disease, CIDP, or anti-MAG neuropathy. It may help doctors better understand these conditions.
This study looks at a treatment made from immune proteins (immunoglobulin M) to treat neuropathy caused by anti-MAG antibodies. It may help improve nerve symptoms in people with this specific type of nerve condition.
This test uses a light device (photobiomodulation) to see if it can help prevent or reduce nerve damage and pain caused by chemotherapy. It is for patients starting cancer treatment.
This trial looks at whether light (photobiomodulation) and laser-like therapy can reduce nerve pain in people who developed neuropathy after chemotherapy. If you match the chemotherapy and language requirements, you may be screened to see if this treatment is safe and helpful for your symptoms.
This trial tests whether a special laser (photobiomodulation) can help slow or improve vision loss from reticular pseudodrusen, a specific type of retinal damage seen in age-related macular degeneration. The laser delivers safe light energy to stimulate healing in the eye.
Hear when a new Anti-MAG Neuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.